

EDITORIAL CONTACTS:

Mary Lou Simmermacher, Agilent  
+1 408 553 2487  
[marylou\\_simmermacher@agilent.com](mailto:marylou_simmermacher@agilent.com)

Barbara Lindheim  
GendeLLindheim BioCom Partners, for BioNanomatrix  
+1 212 918 4650  
[blindheim@biocompartners.com](mailto:blindheim@biocompartners.com)

**Agilent Technologies and BioNanomatrix to Develop Genetic Analysis System Using Nanoscale Whole Genome Imaging Technology**

**SANTA CLARA, Calif., and PHILADELPHIA, Nov. 5, 2007** -- Agilent Technologies Inc. (NYSE: A) and BioNanomatrix Inc. today announced that they have entered into a collaboration to develop a new genetic analysis system combining the two companies' technologies. BioNanomatrix, which develops breakthrough nanoscale whole genome imaging and analytic platforms, will apply its innovative nanoscale single molecule imaging technology to develop consumable chips and reagents, while Agilent will develop the measurement instrumentation platform for the system.

"This collaboration with Agilent provides us with the opportunity to join forces with a global life sciences leader to accelerate the development of our unique nanoscale whole genome imaging technology," said Dr. Michael Boyce-Jacino, chief executive officer of BioNanomatrix. "We now have a partner with strong life sciences expertise and capabilities committed to working with us to develop key life-sciences applications, such as assays for genotoxicity and cytogenetics, as well as potentially DNA sequencing."

BioNanomatrix is developing pioneering technology that enables nanoscale single molecule identification and analysis of the entire genome, delivering single-molecule sensitivity in a highly parallel format. The company's patented analytic platform based on this technology has the potential to provide rapid, comprehensive and cost-effective ultra-high resolution analyses of DNA. The two companies intend to collaborate closely in the development of an integrated system and applications.

"BioNanomatrix's unique nanoscale whole genome imaging and analysis technology, with sensitivity at the level of the single molecule, has the potential to enable a number of important new applications for life sciences research and clinical medicine," said Nick Roelofs, vice president and general manager of the Life Sciences Solutions Unit at Agilent. "We are committed to continuing our leadership in developing important new technologies and solutions for our customers, and we look forward to collaborating with the BioNanomatrix team to enable these powerful new capabilities to reach the marketplace."

Further details of the agreement were not disclosed.

**About BioNanomatrix**

BioNanomatrix is developing breakthrough nanoscale whole genome imaging and analytic platforms for applications in clinical genetics, cancer diagnostics and other biomedical applications. The company is applying its expertise in nanochips, nanodevices and nanosystems to develop its patented platform technology to provide fast, comprehensive, and

low-cost analysis of genomic, epigenomic and proteomic information with sensitivity at the single cell/single molecule level. BioNanomatrix's technologies are licensed exclusively from Princeton University. Founded as a spin-out of Princeton University in 2003, the company is headquartered in Philadelphia, Penn. For more information, visit [www.BioNanomatrix.com](http://www.BioNanomatrix.com).

### **About Agilent Technologies**

Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company's 19,000 employees serve customers in more than 110 countries. Agilent had net revenue of \$5.0 billion in fiscal year 2006. Information about Agilent is available on the Web at [www.agilent.com](http://www.agilent.com).

# # #

NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available on the Agilent news site at [www.agilent.com/go/news](http://www.agilent.com/go/news).